The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids
Open accessAbstract
Glucocorticoids depress bone formation by inhibiting osteoblastogenesis and increasing osteoblast apoptosis. However, the role of bone resorption in the initial rapid phase of bone loss characteristic of glucocorticoid-induced osteoporosis is unexplained, and the reason for the efficacy of bisphosphonates in this condition remains unknown. We report that in murine osteoclast cultures, glucocorticoids prolonged the baseline survival of osteoclasts and antagonized bisphosphonate-induced caspase activation and apoptosis by a glucocorticoid receptor–mediated action. Consistent with the in vitro evidence, in a murine model of glucocorticoid-induced osteoporosis, the number of cancellous osteoclasts increased, even though osteoclast progenitor number was reduced. Moreover, in mice receiving both glucocorticoids and bisphosphonates, the expected proapoptotic effect of bisphosphonates on osteoclasts was abrogated, as evidenced by maintenance of osteoclast numbers and, additionally, loss of bone density. In contrast, bisphosphonate administration prevented glucocorticoid-induced osteoblast apoptosis. These results indicate that the early loss of bone with glucocorticoid excess is caused by extension of the life span of pre-existing osteoclasts, an effect not preventable by bisphosphonates. Therefore, the early beneficial effects of these agents must be due, in part, to prolonging the life span of osteoblasts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020617 · Cited by 5,016
Self-citationManolagas, S. C. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0395 · Cited by 2,568
Self-citationWeinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753 · cited 7×
“We have reported previously that glucocorticoid administration to mice for 27 days (a period representing chronic rather than short-term drug exposure) decreases the number of osteoblast and osteoclast progenitors, decreases the cancellous osteoblast and osteoclast perimeters, and increases osteoblast apoptosis (20).”
InfluentialSelf-citationUnbalanced Repeated-Measures Models with Structured Covariance Matrices
Jennrich, R. I., & Schluchter, M. D. (1986) · Biometrics · doi:10.2307/2530695 · Cited by 1,325
Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis
Saag, K. G., Emkey, R., Schnitzer, T. J., Brown, J. P., Hawkins, F., Goemaere, S., Thamsborg, G., Liberman, U. A., Delmas, P. D., Malice, M.-P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807303390502 · Cited by 1,258 · cited 3×
“Despite the uncertainty about the role of bone resorption in the pathogenesis of osteoporosis induced by long-term glucocorticoid administration, the benefits of bisphosphonate therapy in this disorder have been ascribed solely to antiresorptive effects and preservation of, or increases in, bone density (13, 16, 17),…”
Luckman, S. P., Hughes, D. E., Coxon, F. P., Russell, R. G. G., & Dr. Rogers, M. J. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.4.581 · Cited by 1,176
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin
Plotkin, L. I., Weinstein, R. S., Parfitt, A. M., Roberson, P. K., Manolagas, S. C., & Bellido, T. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6800 · Cited by 890 · cited 2×
“Despite the uncertainty about the role of bone resorption in the pathogenesis of osteoporosis induced by long-term glucocorticoid administration, the benefits of bisphosphonate therapy in this disorder have been ascribed solely to antiresorptive effects and preservation of, or increases in, bone density (13, 16, 17),…”
Self-citationEstrogen promotes apoptosis of murine osteoclasts mediated by TGF–β
Hughes, D. E., Dai, A., Tiffee, J. C., Li, H. H., Mundy, G. R., & Boyce, B. F. (1996) · Nature Medicine · doi:10.1038/nm1096-1132 · Cited by 813
Reid, D. M., Hughes, R. A., Laan, R. F. J. M., Sacco-Gibson, N. A., Wenderoth, D. H., Adami, S., Eusebio, R. A., & Devogelaer, J.-P. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.6.1006 · Cited by 592
Bone loss in response to long-term glucocorticoid therapy
LoCascio, V., Bonucci, E., Imbimbo, B., Ballanti, P., Adami, S., Milani, S., Tartarotti, D., & DellaRocca, C. (1990) · Bone and Mineral · doi:10.1016/0169-6009(91)90139-q · Cited by 384
Research works printed but not linked: 4
- 10.1210/en.138.9.4013 · doi:10.1210/en.138.9.4013 · Paper page
- 2001, Stata Corporation College Station, Texas, USA, 3, 44
- 10.1210/er.21.2.115 · DOI
- 10.1210/en.131.1.114 · doi:10.1210/en.131.1.114 · Paper page
Cited by
Matrix-embedded cells control osteoclast formation
Xiong, J., Onal, M., Jilka, R. L., Weinstein, R. S., Manolagas, S. C., & O'Brien, C. A. (2011) · Nature Medicine · doi:10.1038/nm.2448 · Cited by 1,304
“And third, administration of glucocorticoids potently reduces the number of osteoblasts on bone, as well as the abundance of their precursors in the bone marrow, but not the number of osteoclast”
BackgroundSelf-citationManolagas, S. C. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0024 · Cited by 1,200
Self-citationO’Brien, C. A., Jia, D., Plotkin, L. I., Bellido, T., Powers, C. C., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2004) · Endocrinology · doi:10.1210/en.2003-0990 · Cited by 771
Self-citationSkeletal Involution by Age-associated Oxidative Stress and Its Acceleration by Loss of Sex Steroids
Almeida, M., Han, L., Martin-Millan, M., Plotkin, L. I., Stewart, S. A., Roberson, P. K., Kousteni, S., O'Brien, C. A., Bellido, T., Parfitt, A. M., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m702810200 · Cited by 706
Self-citationGlucocorticoid-Induced Bone Disease
Weinstein, R. S. (2011) · New England Journal of Medicine · doi:10.1056/nejmcp1012926 · Cited by 694
Self-citationKenkre, J., & Bassett, J. (2018) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563218759371 · Cited by 693
Aguirre, J. I., Plotkin, L. I., Stewart, S. A., Weinstein, R. S., Parfitt, A. M., Manolagas, S. C., & Bellido, T. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.060107 · Cited by 494
Self-citationGlucocorticoid-induced osteonecrosis
Weinstein, R. S. (2012) · Endocrine · doi:10.1007/s12020-011-9580-0 · Cited by 428
Self-citationRauch, A., Seitz, S., Baschant, U., Schilling, A. F., Illing, A., Stride, B., Kirilov, M., Mandic, V., Takacz, A., Schmidt-Ullrich, R., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2010.05.005 · Cited by 422
Glucocorticoids Act Directly on Osteoclasts to Increase Their Life Span and Reduce Bone Density
Jia, D., O’Brien, C. A., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2006) · Endocrinology · doi:10.1210/en.2006-0459 · Cited by 394
Self-citationGiant Osteoclast Formation and Long-Term Oral Bisphosphonate Therapy
Weinstein, R. S., Roberson, P. K., & Manolagas, S. C. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0802633 · Cited by 391
Self-citationBisphosphonates: An Update on Mechanisms of Action and How These Relate to Clinical Efficacy
RUSSELL, R. G. G., XIA, Z., DUNFORD, J. E., OPPERMANN, U., KWAASI, A., HULLEY, P. A., KAVANAGH, K. L., TRIFFITT, J. T., LUNDY, M. W., PHIPPS, R. J., et al. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1402.089 · Cited by 391
Glucocorticoids suppress bone formation via the osteoclast.
Kim, H.-J. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28084 · Cited by 384
Recent advances in osteoclast biology
Ono, T., & Nakashima, T. (2018) · Histochemistry and Cell Biology · doi:10.1007/s00418-018-1636-2 · Cited by 384
Riggs, B. L., & Parfitt, A. M. (2005) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.041114 · Cited by 380
Self-citationBellido, T., Ali, A. A., Plotkin, L. I., Fu, Q., Gubrij, I., Roberson, P. K., Weinstein, R. S., O'Brien, C. A., Manolagas, S. C., & Jilka, R. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m307444200 · Cited by 378
Self-citationTranscriptional Regulatory Cascades in Runx2-Dependent Bone Development
Liu, T. M., & Lee, E. H. (2013) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2012.0527 · Cited by 375
Bone loss in inflammatory disorders
Hardy, R., & Cooper, M. S. (2009) · Journal of Endocrinology · doi:10.1677/joe-08-0568 · Cited by 365
Glucocorticoid-Induced Osteoporosis and Osteonecrosis
Weinstein, R. S. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.04.004 · Cited by 364
Self-citationLane, N. E., Yao, W., Balooch, M., Nalla, R. K., Balooch, G., Habelitz, S., Kinney, J. H., & Bonewald, L. F. (2006) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.051103 · Cited by 355
Kerachian, M. A., Séguin, C., & Harvey, E. J. (2009) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2009.02.007 · Cited by 349
Wu, W., Chaudhuri, S., Brickley, D. R., Pang, D., Karrison, T., & Conzen, S. D. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2546 · Cited by 314
Ambrogini, E., Almeida, M., Martin-Millan, M., Paik, J.-H., DePinho, R. A., Han, L., Goellner, J., Weinstein, R. S., Jilka, R. L., O'Brien, C. A., et al. (2010) · Cell Metabolism · doi:10.1016/j.cmet.2009.12.009 · Cited by 309
Self-citationKousteni, S., Li, H., Chen, J., Almeida, M., Plotkin, L. I., Bellido, T., & Manolagas, S. C. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17261 · Cited by 270
Self-citationThe pathogenesis, diagnosis and clinical manifestations of steroid-induced osteonecrosis
Chang, C., Greenspan, A., & Gershwin, M. E. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102460 · Cited by 269
Osseointegration – communication of cells
Terheyden, H., Lang, N. P., Bierbaum, S., & Stadlinger, B. (2012) · Clinical Oral Implants Research · doi:10.1111/j.1600-0501.2011.02327.x · Cited by 265
The osteocyte as a signaling cell
Delgado-Calle, J., & Bellido, T. (2022) · Physiological Reviews · doi:10.1152/physrev.00043.2020 · Cited by 261
Self-citationThe Pathogenesis, Epidemiology and Management of Glucocorticoid-Induced Osteoporosis
van Staa, T. P. (2006) · Calcified Tissue International · doi:10.1007/s00223-006-0019-1 · Cited by 260
Glucocorticoids and bone: consequences of endogenous and exogenous excess and replacement therapy
Hardy, R. S., Zhou, H., Seibel, M. J., & Cooper, M. S. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00097 · Cited by 258
Estrogen Regulates Bone Turnover by Targeting RANKL Expression in Bone Lining Cells
Streicher, C., Heyny, A., Andrukhova, O., Haigl, B., Slavic, S., Schüler, C., Kollmann, K., Kantner, I., Sexl, V., Kleiter, M., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-06614-0 · Cited by 251
RANKL Expression Is Related to the Differentiation State of Human Osteoblasts
Atkins, G. J., Kostakis, P., Pan, B., Farrugia, A., Gronthos, S., Evdokiou, A., Harrison, K., Findlay, D. M., & Zannettino, A. C. (2003) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2003.18.6.1088 · Cited by 245
“Initially, this effect may be counteracted by an increase in the survival of existing osteoclasts,((46)) possibly mediated by a transient increase in the RANKL: OPG ratio.”
BackgroundMechanisms of glucocorticoid-induced osteoporosis.
Canalis, E. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200307000-00013 · Cited by 164
Glucocorticoid dose determines osteocyte cell fate
Jia, J., Yao, W., Guan, M., Dai, W., Shahnazari, M., Kar, R., Bonewald, L., Jiang, J. X., & Lane, N. E. (2011) · The FASEB Journal · doi:10.1096/fj.11-182519 · Cited by 157
Pathogenic mechanisms of glucocorticoid-induced osteoporosis
Chen, M., Fu, W., Xu, H., & Liu, C.-J. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.03.002 · Cited by 146
Yao, W., Cheng, Z., Pham, A., Busse, C., Zimmermann, E. A., Ritchie, R. O., & Lane, N. E. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23954 · Cited by 128
Understanding and managing corticosteroid-induced osteoporosis
Kobza, A. O., Herman, D., Papaioannou, A., Lau, A. N., & Adachi, J. D. (2021) · Open Access Rheumatology Research and Reviews · doi:10.2147/oarrr.s282606 · Cited by 84
“Glucocorticoids inhibit the synthesis and secretion of sex steroids causing a similar effect and as a result contributing to GIOP.20 Insulin-like growth factor 1 (IGF-1) promotes bone formation by stimulating type 1 collagen synthesis, suppressing bone collagen degradation and suppressing osteoblast apoptosis.21 IGF-1…”
BackgroundInfluentialOsteoblasts in Bone Physiology – Mini Review
Rosenberg, N., Rosenberg, O., & Soudry, M. (2012) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10080 · Cited by 64
Balooch, G., Yao, W., Ager, J. W., Balooch, M., Nalla, R. K., Porter, A. E., Ritchie, R. O., & Lane, N. E. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22976 · Cited by 37
Ma, T.-L., Zhu, P., Ke, Z.-R., Chen, J.-X., Hu, Y.-H., & Xie, J. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.891313 · Cited by 9
Self-citationSambrook, P. N., Roux, C., Devogelaer, J.-P., Saag, K., Lau, C.-S., Reginster, J.-Y., Bucci-Rechtweg, C., Su, G., & Reid, D. M. (2012) · Bone · doi:10.1016/j.bone.2011.10.024 · Cited by 3
Metadata
- Authors
- Weinstein, R. S., Chen, J.-R., Powers, C. C., Stewart, S. A., Landes, R. D., Bellido, T., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C.
- Venue
- Journal of Clinical Investigation
- Published
- 2002-04-15
- Volume
- 109
- Issue
- 8
- Pages
- 1041-1048
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W4240799970
- Cited by
- 313
- References
- 35
- FWCI
- 5.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.